Advances in Tobacco Control

Cigarette smoking is the leading cause of death from lung cancer in the United States. That’s why November, Lung Cancer Awareness Month, is a good time to highlight new advances in tobacco control, such as the legislation that came into effect Nov. 1, 2017, in New Jersey that raises the minimum age of legal access to tobacco products to 21.

Read More

A Young Researcher Advocates for Strong Federal Funding

Scientific advancements are made through scientific research. From understanding the basic biology behind a disease to testing how well a drug targets a disease, the majority of this research is funded by the National Institutes of Health (NIH). So, on September 14, 2017, hundreds of people from 37 states and Washington, D.C., from over 300 institutes and organizations, gathered for the 5th Annual Rally for Medical Research with a common message

Read More

FDA Approves New Treatment Option for Breast Cancer

Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the breast cancer community just days before the start of breast cancer awareness month when it added a new molecularly targeted therapeutic to the armamentarium for oncologists treating patients with breast cancer: abemaciclib (Verzenio).

Read More

FDA Approvals for Liver and Stomach Cancer Extend the Reach of Immunotherapy

Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which immunotherapeutics known as checkpoint inhibitors are a treatment option when it expanded the approved uses of nivolumab (Opdivo) and pembrolizumab (Keytruda) to include certain patients with liver cancer and stomach cancer, respectively.

Read More

FDA Approves New Molecularly Targeted Therapeutic for Non-Hodgkin Lymphoma

The flurry of treatments approved by the U.S. Food and Drug Administration (FDA) for treating hematological malignancies continued last week with the approval of the molecularly targeted therapeutic copanlisib (Aliqopa) for the treatment of certain adults with non-Hodgkin lymphoma.

Read More

AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives

Today, the American Association for Cancer Research (AACR) released its seventh annual Cancer Progress Report. The report highlights how federally funded research that provides a deep understanding of the biology of cancer is spurring advances across the clinical cancer care continuum that are improving survival and quality of life for people around the world.

Read More

New Treatment for Adults with Acute Lymphoblastic Leukemia Approved by the FDA

This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel (Kymriah) for treating certain pediatric and young adult patients with acute lymphoblastic leukemia (ALL) was not the only good news for ALL community in August. Earlier in the month, the FDA approved a new molecularly targeted therapeutic called inotuzumab ozogamicin (Besponsa) for treating adults who have B-cell precursor ALL that did not respond to initial treatment or that returned after treatment.

Read More